Leukotriene Inhibition in Animal Models of MS: A Systematic Review
Research on leukotriene inhibitors in animal models showed that blocking certain pathways reduced symptoms of neuroinflammation and demyelination. Specifically, five studies indicated that inhibiting leukotriene B4 or its receptors helped lessen clinical severity in models of experimental autoimmune encephalomyelitis and cuprizone-induced demyelination.
- Most relevant to
- —
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
These findings suggest potential pathways that could contribute to future treatments for Multiple Sclerosis, especially in remyelination and neuroprotection.
What this does not prove
The results are based on animal studies and do not establish clinical efficacy in humans. More rigorous clinical trials are necessary to determine any actual benefits for MS patients.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- 5 · Number of included studies
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-15
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Neuroinflammation, Neuroprotection, Remyelination
Original sources
- Primary evidenceLeukotriene inhibitors in multiple sclerosis: a systematic review of animal studies. ↗DOI: 10.1007/s10787-026-02429-6
Supporting passages (9)
study phaseEligible studies included preclinical investigations of leukotriene inhibitors in MS animal models and risk of bias was assessed using SYRCLE's risk of bias tool for animal studies.
study designFollowing the PRISMA 2020 recommendations, a systematic search was conducted in PubMed, Web of Science, and Scopus.
subjectsEligible studies included preclinical investigations of leukotriene inhibitors in MS animal models and risk of bias was assessed using SYRCLE's risk of bias tool for animal studies.
sample sizeFive studies met the inclusion criteria, reported that inhibition of leukotriene B4 (LTB4) or cysteinyl leukotriene receptor 1 (CysLT1) attenuated clinical severity in experimental autoimmune encephalomyelitis (EAE) and cuprizone-induced demyelination models.
sample size basisMechanistically, the included preclinical studies suggest that leukotriene inhibitors may influence several pathways potentially relevant to MS pathophysiology, including T helper 17 (Th17) cell differentiation, M1-like microglial polarization, and oligodendrocyte precursor cell (OPC) differentiation.
research categoriesLeukotriene inhibitors in multiple sclerosis: a systematic review of animal studies.
findingsFive studies met the inclusion criteria, reported that inhibition of leukotriene B4 (LTB4) or cysteinyl leukotriene receptor 1 (CysLT1) attenuated clinical severity in experimental autoimmune encephalomyelitis (EAE) and cuprizone-induced demyelination models.
limitationsAlthough these mechanistic observations provide biological plausibility for further investigation of these agents as potential repurposed therapies for MS, particularly in the context of remyelination and neuroinflammation, they remain based on preclinical evidence and should therefore be considered hypothesis-generating.
publication datePublication date: 2026-10-15
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.